Day One Biopharmaceuticals, Inc. financial data

Symbol
DAWN on Nasdaq
Industry
Pharmaceutical Preparations
Location
2000 Sierra Point Parkway, Suite 501, Brisbane, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Day One Biopharmaceuticals Holding Co LLC (to 5/26/2021)
Latest financial report
Q1 2024 - May 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.44 K %
Debt-to-equity 7.44 % +42.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 87.4 M shares +18.8%
Common Stock, Shares, Outstanding 87.4 M shares +18.8%
Entity Public Float 759 M USD +8.68%
Common Stock, Value, Issued 9 K USD +28.6%
Weighted Average Number of Shares Outstanding, Basic 86.7 M shares +20.4%
Weighted Average Number of Shares Outstanding, Diluted 86.7 M shares +20.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 143 M USD +45.2%
General and Administrative Expense 84.1 M USD +26.3%
Operating Income (Loss) -227 M USD -37.5%
Earnings Per Share, Basic -2.5 USD/shares -9.65%
Earnings Per Share, Diluted -2.5 USD/shares -9.65%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 270 M USD +449%
Other Assets, Current 322 M USD +20.6%
Assets, Current 326 M USD
Property, Plant and Equipment, Net 185 K USD +157%
Operating Lease, Right-of-Use Asset 259 K USD -58%
Assets 327 M USD +0.95%
Accounts Payable, Current 4.78 M USD +2.64%
Accrued Liabilities, Current 16 M USD +138%
Liabilities, Current 29.8 M USD +30.6%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 29.8 M USD +28.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5 K USD -107%
Retained Earnings (Accumulated Deficit) -521 M USD -67%
Stockholders' Equity Attributable to Parent 297 M USD -1.2%
Liabilities and Equity 327 M USD +0.95%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -49.7 M USD -91.4%
Net Cash Provided by (Used in) Financing Activities 164 M USD -1.15%
Net Cash Provided by (Used in) Investing Activities 89.3 M USD
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 87.4 M shares +18.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 146 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 270 M USD +449%
Deferred Tax Assets, Valuation Allowance 94.4 M USD +75.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Cash and Cash Equivalents, Period Increase (Decrease) -21.6 M USD -119%
Deferred Tax Assets, Gross 94.5 M USD +75.1%
Operating Lease, Liability 300 K USD -58.2%
Depreciation 63 K USD +215%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -209 M USD -33.3%
Lessee, Operating Lease, Liability, to be Paid 308 K USD -59.9%
Property, Plant and Equipment, Gross 243 K USD +106%
Operating Lease, Liability, Current 300 K USD -28.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 424 K USD +2256%
Lessee, Operating Lease, Liability, to be Paid, Year One 424 K USD -7.42%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8 K USD -84.6%
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 2.63 M USD +3.91%
Operating Lease, Payments 1.1 M USD
Additional Paid in Capital 818 M USD +33.5%
Depreciation, Depletion and Amortization 23 K USD +283%
Share-based Payment Arrangement, Expense 42.5 M USD +39.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%